Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
IAOM-US / Pixabay

Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder

According to Juvenile Arthritis News, treating juvenile idiopathic arthritis early helps reduce symptoms, nearly "inactivating" the condition. The Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) JIA Registry found that early…

Continue Reading Early Treatment of Juvenile Idiopathic Arthritis Improves Outcomes, Inactivates Disorder
New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
source: pixabay.com

New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis

  According to a recent article in BioMed Central, an international task force formed in 2018 created guidelines for the treatment of juvenile idiopathic arthritis (JIA). Treatment targets were identified…

Continue Reading New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
Study: Felty’s Syndrome Presents Differently in Pediatric Patients
source: pixabay.com

Study: Felty’s Syndrome Presents Differently in Pediatric Patients

According to a study published in BMC Pediatrics, the rare disease known as Felty's syndrome is primarily known to affects adults between the ages of 50 and 70, but on very rare…

Continue Reading Study: Felty’s Syndrome Presents Differently in Pediatric Patients
ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
source: pixabay.com

ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention

  Janssen R&D, a division of Johnson & Johnson (J&J), has partnered with the UK Biobank and others according to a recent news release by 3BL Media. It is noteworthy…

Continue Reading ICYMI: Johnson & Johnson and the UK Government: Genomics For Disease Prevention
Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
source: pixabay.com

Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis

  According to a recent article in MedPage Today’s 2019 year-end review, the number of life-threatening lung diseases in systemic juvenile idiopathic arthritis (sJIA) patients has been increasing. sJIA is…

Continue Reading Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
source: pixabay.com

The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease

According to a story from Business Wire, the biopharmaceutical company Bristol-Myers Squibb has recently announced that the US Food and Drug Administration (FDA) has granted the company's drug abatacept (marketed…

Continue Reading The FDA Grants Breakthrough Therapy Designation for ORENCIA as a Treatment for Graft vs Host Disease
The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial
source: pixabay.com

The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial

According to a story from Juvenile Arthritis News, the results of a recent phase 3 clinical trial indicate that the drug tofacitinib (marketed as Xeljanz) can be an effective treatment…

Continue Reading The Drug Tofacitinib Appears Effective for Juvenile Idiopathic Arthritis in Clinical Trial
Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease
nastya_gepp / Pixabay

Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease

According to a story from newswise.com, biologic medicines have had a major positive impact on outcomes for patients with the rare disease juvenile idiopathic arthritis (JIA). However, as these medicines…

Continue Reading Doctors Call for Screening of Juvenile Idiopathic Arthritis Patients to Identify Rare Lung Disease

Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease

The number of systemic juvenile idiopathic arthritis patients who develop lung disease (sJIA-LD) is rising in both the U.S., Europe, the Middle East, and Canada. This trend has been notable…

Continue Reading Potential Link Between a Treatment for Systemic Juvenile Idiopathic Arthritis and Lung Disease
Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients
Pexels / Pixabay

Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients

According to a story from Juvenile Arthritis News, a recent study from China has found that early treatment with infliximab (marketed as Remicade) can reduce inflammation and indicators of active…

Continue Reading Early Use of Infliximab Offers Benefits for Juvenile Idiopathic Arthritis Patients
Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis
JillWellington / Pixabay

Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis

According to a story from Juvenile Arthritis News, a recent study has found that the drug leflunomide (marketed as Arava) may be a viable treatment for juvenile idiopathic arthritis patients,…

Continue Reading Study Finds The Drug Arava May be Useful for Juvenile Idiopathic Arthritis

Study Shows The Shared Decision-Making Model Improves Outcomes for JIA Patients

Juvenile idiopathic arthritis (JIA) is a rare condition affecting children. Like all patients, these children are told what treatment they need and then they are expected to comply. However, researchers in…

Continue Reading Study Shows The Shared Decision-Making Model Improves Outcomes for JIA Patients
Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA
stevepb / Pixabay

Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

According to a story from Ankylosing Spondylitis News, the drug Hadlima, which is a biosimilar to the drug Humira (adalimumab), was recently approved by the US Food and Drug Administration…

Continue Reading Biosimilar Drug for Ankylosing Spondylitis gets Approved by the FDA

Study Determines More Research is Needed Regarding the Effect of Body Weight on Juvenile Idiopathic Arthritis

The Study Juvenile idiopathic arthritis (JIA) is a rare disease that causes inflammation in the joints. It is of unknown origin and has no cure. Previous investigations in studies with…

Continue Reading Study Determines More Research is Needed Regarding the Effect of Body Weight on Juvenile Idiopathic Arthritis

ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

A recent article written by Craig Klugman debates the ethical obligations pharmaceutical companies have to conduct clinical trials for drugs which have a likely potential to benefit a patient population…

Continue Reading ICYMI: A Good Business Decision vs. The Right Ethical Choice: Conducting Clinical Trials

Phase 3 Trial Results Continue to Show the Efficacy of Orencia as a Treatment for Juvenile Idiopathic Arthritis

Orencia Orencia (abatacept) is a treatment for juvenile idiopathic arthritis (JIA) that was approved for use in the U.S. for the pediatric patient population in 2008. In Japan, the therapy…

Continue Reading Phase 3 Trial Results Continue to Show the Efficacy of Orencia as a Treatment for Juvenile Idiopathic Arthritis

Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU

Extremely positive results have just been announced from a 5-year follow-up study of a systemic juvenile idiopathic arthritis (sJIA) treatment called Kineret. This treatment has been approved for use in…

Continue Reading Extremely Positive Results from Systemic Juvenile Idiopathic Arthritis 5-year Follow-Up Study in the EU

Investigational Farber Disease Therapy Now has Three FDA Designations

Farber Disease Farber Disease is a rare condition otherwise known as Acid Ceramidase Deficiency. It is a lysosomal storage disease caused by a missing ceramidase enzyme. This is due to…

Continue Reading Investigational Farber Disease Therapy Now has Three FDA Designations

New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients

The most common treatment for autoimmune conditions such as ankylosing spondylitis, plaque psoriasis, Crohn's disease, juvenile idiopathic arthritis, and rheumatoid arthritis is currently a drug called Humira, created by AbbVie.…

Continue Reading New Biosimilar Product to Humira Could Be Cheaper and Just as Effective for Ankylosing Spondylitis Patients

New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China

SOJIA SOJIA stands for systemic-onset Juvenile Idiopathic Arthritis (JIV). It is a very severe form of JIA which causes joint pain, inflammation, recurrent fevers, and a skin rash. Patients often take predinsolone,…

Continue Reading New Potential Treatment for Systemic-Onset Juvenile Idiopathic Arthritis Investigated in China
Close Menu